| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAGLN |
| Uniprot No | Q01995 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMANKGPSYGMSREVQSKIEKKYDEELEERL VEWIIVQCGPDVGRPDRGRLGFQVWLKNGVILSKLVNSLYPDGSKPVKVP ENPPSMVFKQMEQVAQFLKAAEDYGVIKTDMFQTVDLFEGKDMAAVQRTL MALGSLAVTKNDGHYRGDPNWFMKKAQEHKREFTESQLQEGKHVIGLQMG SNRGASQAGMTGYGRPRQIIS |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TAGLN重组蛋白的3篇示例参考文献(注：文献为假设性示例，实际文献需通过学术数据库检索确认)：
---
1. **标题**: *Recombinant Human TAGLN Protein Inhibits Tumor Metastasis via Modulation of Actin Cytoskeleton Dynamics*
**作者**: Zhang Y, Chen L, Wang M.
**摘要**: 本研究通过在大肠杆菌中表达并纯化重组人TAGLN蛋白，发现其能显著抑制乳腺癌细胞的迁移和侵袭。实验表明，TAGLN通过稳定肌动蛋白纤维网络，阻碍细胞伪足形成，提示其在癌症治疗中的潜在应用。
2. **标题**: *Expression and Functional Characterization of TAGLN Recombinant Protein in Vascular Smooth Muscle Differentiation*
**作者**: Smith J, Brown K, Lee S.
**摘要**: 作者利用昆虫细胞系统表达TAGLN重组蛋白，并证实其促进血管平滑肌细胞分化的功能。研究还揭示了TAGLN通过激活SMAD信号通路调控基因表达，为心血管疾病研究提供新靶点。
3. **标题**: *Structural Insights into TAGLN-Actin Interaction Revealed by Recombinant Protein Crystallography*
**作者**: Wang X, Ito H, Tanaka T.
**摘要**: 通过解析重组TAGLN蛋白的晶体结构，本研究阐明了其与肌动蛋白结合的关键结构域，并发现磷酸化修饰可动态调节二者互作，为理解细胞骨架重塑机制提供分子基础。
---
**建议**：实际文献可通过PubMed、Web of Science等平台，以关键词“TAGLN recombinant protein”或“Transgelin expression and purification”检索近年研究。部分经典文献可能发表于*Journal of Biological Chemistry*、*Cellular Signalling*等期刊。
Transgelin (TAGLN) is a conserved actin-binding protein belonging to the calponin family, primarily involved in regulating cytoskeletal dynamics and smooth muscle contraction. It is encoded by the TAGLN gene and is characterized by a molecular weight of approximately 22 kDa, featuring a conserved calponin-like domain that facilitates interactions with actin filaments. Initially identified as a marker for smooth muscle differentiation, TAGLN is highly expressed in vascular smooth muscle cells, myofibroblasts, and certain tumor-associated stromal cells. Its expression is modulated by transforming growth factor-beta (TGF-β) and other signaling pathways linked to cell differentiation, migration, and tissue remodeling.
Recombinant TAGLN protein is engineered through heterologous expression systems, such as E. coli or mammalian cell cultures, to produce purified, bioactive forms for research and therapeutic applications. This recombinant approach enables precise study of TAGLN's roles in physiological and pathological contexts, including vascular development, wound healing, fibrosis, and cancer progression. In cancer biology, TAGLN exhibits context-dependent roles, acting as both a tumor suppressor (e.g., downregulated in colorectal and breast cancers) and a promoter of metastasis (e.g., upregulated in ovarian and prostate cancers).
Researchers utilize recombinant TAGLN to investigate its interaction with cytoskeletal components, its regulation of cell motility, and its potential as a diagnostic biomarker or therapeutic target. Its involvement in epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling further underscores its significance in fibrosis and metastatic diseases. The availability of recombinant TAGLN accelerates mechanistic studies and drug discovery efforts aimed at modulating cytoskeletal dynamics in cardiovascular disorders, fibrosis, and cancer.
×
